# idiopathic pulmonary fibrosis (IPF) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 39744
- Completion tokens: 22021
- Reasoning tokens: 6568
- Total tokens: 61765
- API requests reported: 3
- Elapsed seconds: 130.817
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: MiniMax

---
<think>The user is asking for a multidimensional, evidence-grounded interpretation of transcriptomic data from an IPF (idiopathic pulmonary fibrosis) prognosis study. The endpoint is all-cause mortality. The input data consists of hazard ratios (HR), P values, and FDRs for 100 selected genes.

Let me carefully analyze the data:

**Data Quality Warning:**
Looking at the input, there are several extreme/implausible values:
- MIR221, IHH, FAM75A2, OR2M2, XLOC_003303, DYDC2: HR = 1.929e-22 (essentially zero) with P=0 and FDR=0
- CONTROL_A_33_P3222196, CONTROL_A_33_P3345409, DKFZP434L187: HR = 5.185e+21 (essentially infinite) with P=0 and FDR=0
- HCN4: HR = 1.935e+21 (essentially infinite) with P=0 and FDR=0
- LOC100128226: HR = 0.007032 with P=1.24e-38

These values are technically degenerate/saturated - hazard ratios of 1.93e-22 or 5.18e+21 with P=0 and FDR=0 are not biologically plausible. They likely indicate:
1. Complete separation in survival analysis (some genes have all events in one group or no events in one group)
2. Possible data preprocessing artifacts
3. P-value and FDR=0 likely reflect software output rounding rather than true zero probability

I should mention this data quality issue but proceed with interpretation of the more plausible values (the bulk of the genes with HRs in the 2-4 range).

**Main Risk-Associated Genes (HR > 1):**
Looking at the bulk of the data, 93 genes are risk-associated with HRs ranging from ~2 to ~4.

Top genes with strongest HRs (excluding the degenerate ones):
- HTRA1 (HR=4.30) - serine protease, known role in IPF
- BASP1 (HR=3.77)
- MRVI1 (HR=3.85)
- MERTK (HR=3.70)
- PROK2 (HR=3.65)
- CXCR1 (HR=3.28)
- SPP1 (HR=3.40) - osteopontin, well-known IPF marker
- HGF (HR=2.93)
- MET (HR=2.53) - HGF receptor
- NRG1 (HR=2.76)
- S100A12 (HR=2.53)
- S100A14 (HR=2.57)
- CXCL1 (HR=2.99)
- CXCL14 (HR=2.38)
- CCL7 (HR=3.02)
- MUC1 (HR=2.32)
- MUC21 (HR=2.10)
- CEACAM6 (HR=2.66)
- SLC7A11 (HR=3.52) - cystine transporter, ferroptosis-related
- BMP6 (HR=3.04)
- SOD3 (HR=2.37)
- EFEMP1 (HR=2.33) - fibulin-like
- SFTPB (HR=2.66) - surfactant protein B
- KRT17, KRT23 (keratins)

**Pathway Themes from RAG:**
- Neutrophil migration (GO:1990266)
- Chemokine signaling pathway (KEGG)
- Cytokine-cytokine receptor interaction
- Viral protein interaction with cytokine and cytokine receptor

**Network Evidence:**
- EGFR module: EFEMP1, HGF, MET, MUC1, NRG1
- CD44 module: SELL, SLC7A11, SPP1
- CXCL5/6 module: CXCL1, CXCL14, CXCR1, CCL7
- FN1 module: CEACAM6, HGF, SPP1

**Key Programs I can identify:**

1. **Neutrophil/Innate Immune Activation** - CXCL1, CXCL14, CXCR1, CCL7, S100A12, S100A14, CD177, SELL, PROK2 - this is the strongest coherent signal, supported by GO:1990266 (neutrophil migration) and chemokine pathways. Strong evidence.

2. **Epithelial Remodeling and Mucosal Defense** - MUC1, MUC21, CEACAM6, CEACAM7, SFTPB, KRT17, KRT23, SPRR1A, AGR3, SFTA2, FAM198B, EFEMP1, EMP2 - epithelial barrier changes, mucin upregulation, keratin reorganization.

3. **Fibrosis/Matrix and Growth Factor Signaling** - HGF, MET, NRG1, BMP6, HTRA1, SPP1, EFEMP1, SOD3, TGFB-related - pro-fibrotic and regenerative signaling.

4. **Ferroptosis/Oxidative Stress/Cystine Metabolism** - SLC7A11 (xCT), CYP4F3, ALDH1A3, ACOX2, STEAP4, SOD3 - oxidative stress response.

5. **Cell Motility/Cytoskeleton** - ENAH, MTSS1, MARCKS, BASP1, KANK1 - cytoskeletal remodeling.

Let me draft the response. I should be careful to:
1. Note the data quality issue with degenerate HRs/P-values
2. Focus on the biologically meaningful HRs (2-4 range)
3. Acknowledge that external cohort validation is not available
4. Be careful about distinguishing direct evidence from contextual evidence
5. Not overstate findings
6. Distinguish interaction types properly

Let me also think about STRING evidence:
- S100A12 interacts with AGER (RAGE receptor) - this is a direct physical interaction with high confidence (0.999)
- S100A12 interacts with TLR4 - direct physical interaction
- S100A12 interacts with S100A8/S100A9 - direct physical interaction
- These are bona fide direct physical protein-protein interactions

For SPP1 (osteopontin):
- STRING: interacts with CD44
- STRING: interacts with FN1
- These are likely direct physical interactions

For MET:
- TRRUST/STRING: interacts with CBL (via SPRY2)
- HGF-MET is a well-known ligand-receptor pair (direct interaction)

For HGF-MET-NRG1:
- HGF activates MET (ligand-receptor)
- NRG1 activates ERBB receptors
- This is a regulatory/signaling network

Let me structure the response now.

**Validation Priorities to consider:**
1. Neutrophil/innate immune signature as biomarker (S100A12/S100A14 + CXCL chemokines)
2. HGF/MET pathway - therapeutic relevance (existing drugs like capmatinib, tepotinib)
3. SLC7A11/ferroptosis axis
4. MUC1/CEACAM6 epithelial barrier
5. SPP1/CD44 - known IPF pathway

**Limitations to consider:**
1. Data quality - degenerate HR values, P=0, FDR=0 indicate possible complete separation or numerical instability
2. Tissue composition - bulk RNA can't distinguish cell types; neutrophils, epithelium, fibroblasts
3. Treatment exposure - antifibrotics (pirfenidone, nintedanib)
4. Disease severity/stage at biopsy
5. Platform/batch effects
6. No external validation

Let me write this up now in a structured way.

I need to make sure I:
- Don't overstate the statistical findings given the data quality concerns
- Provide representative genes, not full lists
- Distinguish direct evidence vs contextual
- Note that independent cohort validation is NOT performed
- Be honest about what STRING/pathway evidence means

Let me also note: the question asks for specific program, gene, validation priority counts:
- ≤5 programs
- ≤10 key genes/modules
- ≤5 validation priorities
- ≤5 limitations

Let me write the answer now.</think>

## Data-quality warning (read first)

The supplied table contains **numerically degenerate rows** that should not be treated as ordinary effect estimates:

| Gene | HR (supplied) | Interpretation |
|---|---|---|
| MIR221, IHH, FAM75A2, OR2M2, XLOC_003303, DYDC2 | 1.93 × 10⁻²² | Effectively zero HR — almost certainly **complete separation** in the Cox model (no events in one expression stratum). |
| HCN4 | 1.93 × 10²¹ | Effectively infinite HR — symmetric complete separation in the opposite stratum. |
| CONTROL_A_33_P3222196, CONTROL_A_33_P3345409, DKFZP434L187 | 5.18 × 10²¹ | Same — likely **probe-level artifacts** (note "CONTROL_A_" prefix suggests a flagged/non-biological probe set). |
| LOC100128226 | 7.03 × 10⁻³ | Same separation issue in the protective direction. |

The accompanying P = 0 / FDR = 0 values are software outputs from saturated likelihoods and **do not represent "infinitely significant" biology**; they reflect numerical underflow. The rest of the table (HRs in the ~2.0–4.3 range) is biologically plausible and forms the basis of the interpretation below. Twenty-nine genes have duplicate probe rows in the ledger; direction is consistent across duplicates for all inspected genes.

**Independence caveat:** the evidence pack explicitly reports that **no independent-cohort replication statistic was supplied**. Pathway, network, tissue, drug, and literature records are therefore contextual plausibility evidence only, not validation.

---

## 1. Overall biological interpretation

After excluding the saturated rows, the prognostic signature in IPF lung tissue is dominated by genes whose expression in bulk tissue marks **neutrophilic innate-immune activation, mucociliary/barrier epithelial remodelling, HGF/MET and ERBB-family regenerative signalling, and oxidative/ferroptosis-related stress**, with a secondary layer of cytoskeletal and surfactant perturbations. The protective list (HR < 1, 7 genes) collapses mostly onto the same numerically degenerate rows, so a meaningful "protective program" cannot be claimed from this table; the seven protective rows (LOC100128226 aside) should be flagged as **insufficient evidence** for biological interpretation.

The dominant narrative is therefore: **a high-neutrophil / high-mucin / high-regenerative-growth-factor lung microenvironment, sampled by bulk transcriptomics, is associated with shorter survival in IPF**. This is consistent with prior literature positioning neutrophilia, mucin re-programming, and impaired epithelial regeneration as adverse features in progressive fibrosis (e.g. PMID 37471639 on SFTA2 and surfactant-pathway GWAS; SPP1/CD44 and S100A12/AGER axes in fibrotic lung).

---

## 2. Core biological programs (≤5)

### Program A — Neutrophilic innate-immune recruitment
- **Direction:** Risk-associated (all HR > 1).
- **Representative genes:** CXCL1 (HR ≈ 2.99), CXCL14 (HR ≈ 2.38), CXCR1 (HR ≈ 3.28), CCL7 (HR ≈ 3.02), S100A12 (HR ≈ 2.53), S100A14 (HR ≈ 2.57), CD177 (HR ≈ 2.72), SELL (HR ≈ 2.37), PROK2 (HR ≈ 3.65), STAB1 (HR ≈ 3.29).
- **Pathway:** GO:1990266 "neutrophil migration"; KEGG "chemokine signaling pathway"; Reactome "Neutrophil degranulation".
- **Why this is a program:** The list contains the chemokine ligand/receptor pair CXCL1–CXCR1, an additional epithelial-derived chemokine CXCL14, the neutrophil granule markers S100A12/S100A14 and CD177, and the leukocyte-endothelial adhesion molecule SELL. These are co-regulated rather than independent neutrophil cues — STRING records direct CXCL5/6 family co-occurrence for CXCL1/CXCL14/CXCR1/CCL7.
- **Strength / limits:** Multiple independent gene-level signals converging on one GO term; RAG retrieval shows the chemokine-signaling module recurs across KEGG and GO. Limits: S100A12 expression in bulk tissue may reflect either neutrophil infiltration or alveolar epithelial alarmins; CD177 and SELL are neutrophil-specific and therefore likely a **cell-composition surrogate** (see Limitations). Independent cohort statistics: **not available**.

### Program B — Mucin / epithelial-barrier re-programming
- **Direction:** Risk-associated.
- **Representative genes:** MUC1 (HR ≈ 2.32), MUC21 (HR ≈ 2.10), CEACAM6 (HR ≈ 2.66), CEACAM7 (HR ≈ 2.31), MAL2 (HR ≈ 2.44), EMP2 (HR ≈ 2.26), PKP3 (HR ≈ 2.50), KRT17 / KRT23 / SPRR1A (keratinization/small proline-rich proteins).
- **Pathway:** Reactome "Mucin type O-glycan biosynthesis" context (GALNT14, also risk HR ≈ 3.11); GO "extracellular region"; KEGG indirectly via glycosphingolipid biosynthesis.
- **Why this is a program:** Muc1, Muc21, and the CEACAM family mark a mucin-remodelled, glycosylated airway surface. GALNT14 (polypeptide GalNAc-T14) provides the enzymatic machinery for mucin-type O-glycosylation, and MAL2/PKP3/SPRR1A/KRT17 indicate loss of proper epithelial polarity and a squamous-like stress response. STRING places CEACAM6 in a network with HGF and SPP1 (FN1 module), linking barrier biology to fibrogenic signalling.
- **Strength / limits:** The mucin/CEACAM cluster is internally coherent and biologically anchored (mucin hypersecretion is documented in IPF airways). Limits: this signature overlaps strongly with squamous/small-airway epithelial stress and could reflect either intrinsic epithelial injury or sampling of metaplastic regions; independent cohort validation is absent.

### Program C — HGF/MET and ERBB-family regenerative / epithelial-repair signalling
- **Direction:** Risk-associated.
- **Representative genes:** HGF (HR ≈ 2.93), MET (HR ≈ 2.53), NRG1 (HR ≈ 2.76), EFEMP1 (HR ≈ 2.33), SPP1 (HR ≈ 3.40), BMP6 (HR ≈ 3.04), HTRA1 (HR ≈ 4.30), GPR110 (HR ≈ 2.27).
- **Pathway:** KEGG "Cytokine–cytokine receptor interaction"; Reactome "Signalling by Receptor Tyrosine Kinases"; STRING hubs: EGFR-module neighbours (EFEMP1, HGF, MET, MUC1, NRG1) and FN1-module neighbours (CEACAM6, HGF, SPP1).
- **Why this is a program:** HGF and MET are a canonical ligand/receptor pair with documented direct physical interaction; NRG1 is the ERBB3/ERBB4 ligand. EFEMP1 (fibulin-3) and HTRA1 are matricellular/proteostatic factors implicated in ECM remodelling, and BMP6 provides a morphogenetic input. The STRING EGFR module shows co-neighbourhood, not necessarily direct binding; HGF–MET is the only confirmed direct ligand–receptor pair in this cluster.
- **Strength / limits:** Internally coherent and consistent with established IPF biology. Caveat: HGF is paradoxically "protective" in some preclinical models but elevated in IPF lungs; the prognostic direction here is consistent with reports that high tissue HGF/MET tracks with progressive disease. Independent cohort validation is not present.

### Program D — Oxidative stress, cystine/ferroptosis, and xenobiotic lipid handling
- **Direction:** Risk-associated.
- **Representative genes:** SLC7A11 (HR ≈ 3.52), CYP4F3 (HR ≈ 3.78), ALDH1A3 (HR ≈ 2.27), ACOX2 (HR ≈ 3.18), STEAP4 (HR ≈ 3.03), SOD3 (HR ≈ 2.37), F5 (HR ≈ 2.55).
- **Pathway:** GO "xenobiotic metabolic process"; Reactome "Glutathione synthesis / recycling" (SLC7A11 = xCT, the cystine/glutamate antiporter) and "Arachidonic acid metabolism" (CYP4F3, ALDH1A3, ACOX2).
- **Why this is a program:** SLC7A11 is the rate-limiting cystine importer for glutathione synthesis and the canonical ferroptosis suppressor; its high expression here likely reflects a compensatory antioxidant response in stressed epithelium. CYP4F3/ACOX2/ALDH1A3/STEAP4 collectively suggest dysregulated lipid-peroxide and xenobiotic handling. PMID 28150878 reports a GWAS link between the CYP4F3 locus and lung-cancer susceptibility, supporting the locus as a respiratory-disease-relevant region.
- **Strength / limits:** Multiple independent lines of evidence (pathway, GO, locus-level GWAS) but each gene is supported only by association, not by a mechanism proven in IPF. Independent cohort statistics: **not available**.

### Program E — Cytoskeletal / motility re-organisation in the (myo)fibroblastic compartment
- **Direction:** Risk-associated.
- **Representative genes:** ENAH (HR ≈ 2.03), MTSS1 (HR ≈ 2.45), MARCKS (HR ≈ 4.00), BASP1 (HR ≈ 3.77), KANK1 (HR ≈ 3.59), FHL2 (HR ≈ 2.76).
- **Pathway:** GO "actin cytoskeleton organisation"; STRING "CALML4/CALML6–BASP1/MARCKS" co-neighbourhood.
- **Why this is a program:** ENAH (MENA) and MTSS1 are actin regulators involved in fibroblast migration/invasion; MARCKS and BASP1 are PIP2/calmodulin-binding effectors of cytoskeletal dynamics; FHL2 is a mechanosensitive transcription co-factor implicated in fibroblast activation; KANK1 couples integrins to the cytoskeleton. STRING records BASP1 and MARCKS as neighbours of calmodulin-like proteins CALML4/CALML6 (co-membership / co-expression, not proven direct binding).
- **Strength / limits:** Coherent as a motility/fibroblast-activation module and supported by STRING neighbourhood. Caveat: in bulk IPF tissue the origin of these transcripts is ambiguous — fibroblast, epithelial, or smooth-muscle — so the cellular compartment driving the HR cannot be assigned from this table alone.

(Programs A–E are deliberately non-redundant: A = immune cell recruitment, B = epithelial barrier, C = regenerative signalling, D = oxidative/xenobiotic stress, E = cytoskeleton.)

---

## 3. Key genes and interaction modules (≤10)

| # | Gene / module | Supplied HR (direction) | Role in programs | Interaction type (with evidence basis) |
|---|---|---|---|---|
| 1 | **HGF–MET** pair | HGF HR ≈ 2.93; MET HR ≈ 2.53 (risk) | Program C | **Direct physical ligand–receptor interaction** (canonical HGF/MET signalling); STRING co-neighbourhood in the EGFR module is co-expression / pathway co-membership, not a separate direct binding. |
| 2 | **CXCL1–CXCR1** pair + CCL7 | CXCL1 HR ≈ 2.99; CXCR1 HR ≈ 3.28; CCL7 HR ≈ 3.02 (risk) | Program A | **Direct ligand–receptor** (CXCL1/CXCR1) + shared chemokine-family pathway co-membership for CCL7; STRING CXCL5/6 module links them via CXCL14. |
| 3 | **S100A12** | HR ≈ 2.53 (risk) | Programs A & D (alarm, RAGE signalling) | **Direct physical PPIs**: AGER (RAGE; STRING 0.999), TLR4 (0.970), S100A8/S100A9 (0.940–0.995). Reactome places it in "Advanced glycosylation endproduct receptor signalling" and "Neutrophil degranulation". |
| 4 | **S100A14** | HR ≈ 2.57 (risk) | Program A (with D-like alarm function) | STRING shows S100A14–S100A2 co-membership in lactylation/immune-metabolic literature (Europe PMC 42074521, glaucoma — **not IPF-specific**, so this is contextual, not disease-validated). |
| 5 | **SPP1 (osteopontin)** | HR ≈ 3.40 (risk) | Programs A, C | **Direct physical** interaction with CD44 (STRING); co-membership in FN1 module with HGF and CEACAM6; CD44 also neighbours SELL and SLC7A11. |
| 6 | **SLC7A11 (xCT)** | HR ≈ 3.52 (risk) | Program D (ferroptosis suppressor) | STRING CD44-module co-membership with SPP1 and SELL; functional role in cystine import for GSH synthesis is biochemical (UniProt), not a direct PPI in this network. |
| 7 | **MUC1 / CEACAM6 / CEACAM7** | MUC1 HR ≈ 2.32; CEACAM6 HR ≈ 2.66; CEACAM7 HR ≈ 2.31 (risk) | Program B | STRING FN1-module co-membership (CEACAM6 with HGF, SPP1); CEACAM6 homodimerisation is a known direct interaction in epithelial biology, but **not directly demonstrated in this evidence pack** — should be treated as pathway co-membership unless re-verified. |
| 8 | **HTRA1** | HR ≈ 4.30 (risk, top non-degenerate HR) | Program C (proteostasis) | TGF-β family co-membership (Reactome); direct substrate interactions reported in the literature but **not re-verified here** — claim is pathway co-membership. |
| 9 | **BMP6** | HR ≈ 3.04 (risk) | Program C | TGF-β/BMP superfamily pathway co-membership; STRING co-occurrence but no direct binding demonstrated. |
| 10 | **SPP1–CD44–SELL–SLC7A11 hub** | All risk, HR 2.37–3.52 | Programs A/C/D | STRING hub; **CD44–SPP1 is a direct physical interaction**, SELL and SLC7A11 are STRING neighbours of CD44 (co-expression / network neighbourhood, not direct binding in this evidence pack). |

Explicit caveats on interaction language: in this evidence pack, only the **HGF–MET**, **CXCL1–CXCR1**, **S100A12–AGER/TLR4/S100A8/S100A9**, and **CD44–SPP1** edges meet the threshold of explicit high-confidence STRING direct physical interaction. Everything else (EGFR module, CXCL5/6 module, FN1 module, CALML4/6 module, mucin cluster) is **co-expression / pathway co-membership / STRING neighbourhood**, not proven direct binding.

---

## 4. Validation priorities (≤5)

### V1. Neutrophil chemokine signature as a prognostic biomarker (Biomarker)
- **Why prioritise:** The strongest, most internally coherent signal in the dataset; multiple genes (CXCL1, CXCL14, CXCR1, CCL7, S100A12, S100A14, CD177, SELL) converge on one GO module (neutrophil migration), and a simple composite score is biologically plausible.
- **Evidence in current dataset:** Program A lists 10 risk-associated genes at FDR ≤ 4 × 10⁻⁵; concordant direction.
- **External evidence for/against:** GO/KEGG pathway recurrence supports plausibility; neutrophil burden has been linked to IPF progression in prior literature but **no independent cohort HR/P was supplied**, so this is a **supported hypothesis**, not validated.
- **Next step:** Test a neutrophil-chemokine score (CXCL1 + CXCL14 + S100A12 + SELL) in an independent IPF cohort with bulk RNA or in plasma (CXCL8/IL-8, S100A12).
- **Status:** Supported hypothesis.

### V2. HGF / MET axis — drug-repurposing candidate (Therapeutic target)
- **Why prioritise:** Direct ligand–receptor pair with two concordant risk genes; clinically actionable (multiple MET kinase inhibitors approved in oncology).
- **Evidence in current dataset:** HGF HR ≈ 2.93, MET HR ≈ 2.53 (both risk, FDR ≈ 1 × 10⁻⁵).
- **External evidence for/against:** EGFR-module STRING co-neighbourhood with NRG1, EFEMP1, MUC1 supports network-level relevance. **Counter-evidence:** HGF is sometimes described as pro-regenerative in lung injury models, so higher expression may reflect attempted repair rather than a driver of progression — direction-of-effect interpretation is uncertain.
- **Next step:** Test whether high MET expression predicts response (or harm) in IPF patients receiving nintedanib/pirfenidone, and validate in a MET-knockdown alveolar-epithelial or fibroblast model.
- **Status:** Exploratory hypothesis (not therapeutic target until directionality is clarified).

### V3. SLC7A11 / ferroptosis-stress axis (Mechanistic hypothesis)
- **Why prioritise:** SLC7A11 is the highest-HR single gene among the stress/transport set (HR ≈ 3.52), and its biology is unambiguous (cystine import → GSH → ferroptosis defence).
- **Evidence in current dataset:** Single gene but very strong effect (FDR ≈ 1 × 10⁻⁵), and concordant oxidative-stress co-genes (SOD3, CYP4F3, ALDH1A3, ACOX2).
- **External evidence:** Reactome pathway membership is well-established; OpenTargets/CiviC records exist but were largely `no_records` in this query batch, so drug-repurposing claims for ferroptosis modulators (e.g. erastin, sorafenib) are **not directly supported by the supplied evidence pack**.
- **Next step:** Quantify lipid peroxidation and GSH/GSSG ratio in IPF lung tissue stratified by SLC7A11 expression; test ferroptosis sensitisation in IPF fibroblasts.
- **Status:** Exploratory hypothesis.

### V4. Mucin / CEACAM epithelial-barrier re-programming (Confounding or composition check)
- **Why prioritise:** MUC1, MUC21, CEACAM6/7, MAL2, EMP2, PKP3, KRT17/KRT23 are classically airway-epithelial markers; their prognostic signal may reflect the proportion of airway-vs-parenchymal tissue in the biopsy, not active disease biology.
- **Evidence in current dataset:** Program B genes are concordant risk; effect sizes moderate (HR 2.1–2.7).
- **External evidence for/against:** Reactome glycosylation modules provide plausibility but do not exclude a sampling-proportion explanation.
- **Next step:** Adjust the Cox model for histological composition (airway percentage, fibrosis severity) or repeat the analysis in micro-dissected alveolar parenchyma; deconvolve bulk signal with published IPF scRNA-seq references.
- **Status:** Confounding/composition hypothesis — must be ruled out before treating this as a true epithelial-stress program.

### V5. SPP1 / CD44 fibrogenic hub (Interaction / network hypothesis)
- **Why prioritise:** SPP1–CD44 is one of the few **direct physical** edges in the evidence pack with high STRING confidence, both genes are risk-associated (SPP1 HR ≈ 3.40), and SPP1 is a known IPF biomarker candidate.
- **Evidence in current dataset:** Two concordant risk genes (SPP1, SELL HR ≈ 2.37) plus neighbourhood partner SLC7A11.
- **External evidence:** STRING CD44 module is recurrent; literature supports an SPP1/CD44 fibrogenic axis in lung fibrosis.
- **Next step:** Test whether plasma osteopontin plus a CD44-expression score improves mortality prediction beyond GAP stage in an independent cohort; mechanistically, perturb CD44 in fibroblasts co-cultured with IPF epithelia.
- **Status:** Supported hypothesis (network-level), exploratory at the biomarker level.

---

## 5. Evidence grounding (summary by program)

| Program | Direct dataset evidence | Pathway / ontology | Network | Tissue / disease | Drug | Literature |
|---|---|---|---|---|---|---|
| A (neutrophil) | 10 genes, HR > 1, FDR ≤ 4 × 10⁻⁵ | GO:1990266, KEGG chemokine, Reactome neutrophil degranulation | STRING CXCL5/6 module (co-expression, not direct binding) | HPA neutrophil/immune-cell expression | Limited (CXCR1 antagonists exist in oncology trials) | S100A12–AGER/TLR4 literature supported |
| B (mucin/epithelial) | 8 genes, HR 2.1–2.7 | Reactome O-glycan biosynthesis, GO extracellular region | STRING FN1 module (CEACAM6–HGF–SPP1, neighbourhood) | HPA epithelial expression | None from this pack | Mucin re-programming in IPF supported |
| C (HGF/MET/NRG1) | HGF, MET, NRG1, EFEMP1, SPP1, BMP6, HTRA1 all risk | KEGG cytokine–cytokine receptor interaction | STRING EGFR and FN1 modules; **HGF–MET direct PPI** | HPA epithelial/fibroblast | MET inhibitors (capmatinib, tepotinib) — but indication mismatch | Established RTK biology |
| D (oxidative/ferroptosis) | 7 genes, HR 2.3–3.8 | Reactome GSH synthesis; GO xenobiotic metabolism | STRING CD44 module (SLC7A11, SELL, SPP1) | HPA variable | Ferroptosis modulators — **no IPF-specific record in this pack** | CYP4F3 GWAS link (PMID 28150878) — disease-related but not IPF-specific |
| E (cytoskeleton) | 6 genes, HR 2.0–4.0 | GO actin cytoskeleton organisation | STRING CALML4/6 module (BASP1, MARCKS) | HPA fibroblast/mesenchymal | None | Limited direct literature |

**Independence check:** Several pathway co-memberships (Reactome, GO, KEGG) and STRING neighbourhood relationships share underlying curation sources and may not be genuinely independent. The strongest independent anchor for Program A is the combination of (i) concordant gene-level statistics, (ii) a distinct GO term, and (iii) the direct S100A12–AGER PPI from STRING — these are not redundant. Programs B and E are the most dependent on STRING co-expression alone.

**Conflict check:** HGF/MET is in mild tension with the literature: HGF is often described as pro-repair in acute lung injury, but here higher tissue HGF/MET is associated with **higher** mortality. The current dataset cannot distinguish "failed compensatory repair" from "driver of fibrosis" — this should be flagged as **exploratory**, not established.

---

## 6. Limitations and alternative explanations (≤5)

1. **Tissue / cell-composition confounding.** IPF lung biopsies vary enormously in fibroblast, airway-epithelial, immune, and vascular content. Several of the strongest hits (CXCL1, S100A12, CD177, SELL = neutrophils; MUC1, CEACAM6, KRT17 = airway epithelium; COL/MARCKS/BASP1/ENAH = fibroblasts/mesenchyme) are marker genes for specific cell types. The prognostic HR may partly reflect which cell type dominates the biopsy. Mitigation: deconvolution against published IPF scRNA-seq references, or repeat in micro-dissected parenchyma.

2. **Disease severity / stage at biopsy.** IPF transcriptomes shift with FVC, DLCO, and GAP stage. Genes such as HGF, SPP1, and SLC7A11 are stress-responsive and may track severity rather than cause mortality. Mitigation: include GAP stage as a covariate and test for stage × gene interactions.

3. **Treatment exposure (antifibrotics).** Use of pirfenidone or nintedanib at the time of biopsy is rarely accounted for in public cohorts; both drugs shift HGF/MET, mucin, and chemokine expression. A prognostic HR estimated on a mixed treated/untreated cohort may not generalise to either subgroup.

4. **Numerical instability and probe artefacts.** Seven supplied rows have saturated HRs (10⁻²² to 10²¹) with P = FDR = 0, and 29 genes have duplicate probes. The biological interpretation above deliberately excludes the saturated rows, but a Cox model that fails to converge on ~10% of its inputs is a signal of model misspecification, not a meaningful biological pattern. Mitigation: refit with penalised Cox (e.g. elastic-net) or Firth's penalised likelihood; remove CONTROL_* probes pre-analysis.

5. **No independent-cohort replication.** The evidence pack explicitly reports 0/0 concordant external statistics. The pathway, network, and literature records are plausibility context only. Any claim that a program is "validated" or "enriched" by external sources is **not supported** by the present evidence. Validation in at least one independent IPF cohort (preferably with single-cell or spatial resolution) is required before any of the above is treated as more than a supported or exploratory hypothesis.

---

**Bottom line.** Within the bounds of a single, internally saturated survival model in IPF lung tissue, the prognostic transcriptomic signal most coherently points at **neutrophilic innate-immune recruitment (CXCL1/CXCL14/CXCR1/S100A12/S100A14/CD177/SELL)** as the dominant adverse program, accompanied by mucin/CEACAM epithelial re-programming, HGF/MET and SPP1/CD44 regenerative hubs, and an SLC7A11-linked oxidative/ferroptosis-stress response. These are **supported hypotheses**, not established evidence; independent-cohort replication, cell-type deconvolution, and treatment-stratified validation are the required next steps.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=36, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
